Search





Search





Markets
/
Stocks
/
nasdaq-cort
/

Corcept Therapeutics Inc

CORT

Add to Watchlist

57.080USD

+5.920+11.57%

Close 05/13, 16:00（ET）Quotes delayed by 15 min

6.13BMarket Cap

124.63P/E TTM



Corcept Therapeutics Inc

57.080

+5.920+11.57%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Corcept Therapeutics Inc

Currency: USD Updated: 2026-05-12

Key Insights

Corcept Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 69 out of 156 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 73.40.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Corcept Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

69 / 156

Overall Ranking

168 / 4490

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Corcept Therapeutics Inc Highlights

StrengthsRisks

Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 57.85% year-on-year.

Overvalued

The company’s latest PE is 111.71, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 76.88M shares, decreasing 9.91% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 511.00 shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.11.

Analyst Rating

Based on 6 analysts

Buy

Current Rating

73.400

Target Price

+40.40%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-12

The current financial score of Corcept Therapeutics Inc is 8.53, ranking 55 out of 156 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 164.90M, representing a year-over-year increase of 4.89%, while its net profit experienced a year-over-year increase of 254.58%.

Score

Industry at a Glance

Previous score

8.53

Change



Financials

8.50

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.63

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.17

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.37

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Corcept Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-05-12

The current valuation score of Corcept Therapeutics Inc is 4.51, ranking 155 out of 156 in the Pharmaceuticals industry. Its current P/E ratio is 111.71, which is 2.19% below the recent high of 114.15 and 82.68% above the recent low of 19.35.

Score

Industry at a Glance

Previous score

4.51

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 69/156

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-12

The current earnings forecast score of Corcept Therapeutics Inc is 7.33, ranking 104 out of 156 in the Pharmaceuticals industry. The average price target is 137.50, with a high of 144.90 and a low of 121.00.

Score

Industry at a Glance

Previous score

7.33

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 6 analysts

Buy

Current Rating

73.400

Target Price

+43.36%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

174

Total

Median

Average

Company name

Ratings

Analysts

Corcept Therapeutics Inc

CORT

Amgen Inc

AMGN

Biogen Inc

BIIB

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

Vertex Pharmaceuticals Inc

VRTX

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-12

The current price momentum score of Corcept Therapeutics Inc is 9.34, ranking 19 out of 156 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 55.03 and the support level at 45.25, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.38

Change

-0.04

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

0.723

Buy

RSI(14)

78.126

Buy

STOCH(KDJ)(9,3,3)

85.049

Overbought

ATR(14)

2.311

High Vlolatility

CCI(14)

163.976

Buy

Williams %R

6.716

Overbought

TRIX(12,20)

1.025

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

52.554

Buy

MA10

51.579

Buy

MA20

48.725

Buy

MA50

41.960

Buy

MA100

43.628

Buy

MA200

60.003

Sell

Institutional Confidence

Currency: USD Updated: 2026-05-12

The current institutional shareholding score of Corcept Therapeutics Inc is 7.00, ranking 52 out of 156 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 71.62%, representing a quarter-over-quarter decrease of 14.25%. The largest institutional shareholder is James Simons, holding a total of 5.76M shares, representing 5.36% of shares outstanding, with 7.40% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

11.05M

+1.03%

Ingalls & Snyder LLC (Asset Management)

7.20M

-6.53%

Renaissance Technologies LLC

Star Investors

5.76M

-5.43%

Baker (George Leonard Jr.)

5.41M

+1.88%

Parallel Advisors, LLC

3.88M

+0.20%

State Street Investment Management (US)

2.99M

+0.53%

Belanoff (Joseph K)

2.98M

Geode Capital Management, L.L.C.

2.67M

+37.98%

Risk Assessment

Currency: USD Updated: 2026-05-12

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Corcept Therapeutics Inc is 2.94, ranking 111 out of 156 in the Pharmaceuticals industry. The company's beta value is 0.36. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Corcept Therapeutics Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.